Use of Cyclobenzaprine After Vaginal Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2013 by NorthShore University HealthSystem Research Institute.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Evanston Continence Center, NorthShore University HealthSystem Research Institute Identifier:
First received: March 4, 2010
Last updated: July 23, 2013
Last verified: July 2013

The management of post-operative pain in patients after vaginal surgery provides many unforeseen challenges. Although vaginal surgery is considered a minimally invasive approach for the repair of pelvic floor prolapse and urinary incontinence, patients may still experience varying degrees of discomfort and post-operative pain. Narcotics, however, can introduce a host of problems in addition to the potential addictive properties of the medication. A vicious cycle ensues as patients seek better pain control at the expense of worsening constipation, but without adequate control of pain after surgery, voiding dysfunctions are often exaggerated.

Cyclobenzaprine (Flexeril®) in conjunction with NSAIDs has long been the basis for management of acute musculoskeletal injuries, but the practice of prescribing this centrally acting muscle relaxant for post-operative patients has also been successful in the management of pain.

An online search of medical databases revealed that there are currently no published retrospective or prospective studies determining the efficacy of cyclobenzaprine in post surgical patients in conjunction with traditional pain management. The investigators hypothesize among healthy patients undergoing elective vaginal surgery for pelvic organ prolapse, the short-term use of a muscle relaxant could reduce the spasticity of the pelvic floor muscle attributable to surgery and thereby reduce the use of narcotics. Consequently, the reduction of narcotics and the control of post-surgical pain may also hasten the return of normal urinary and defecatory function.

Condition Intervention
Postoperative Pain
Drug: cyclobenzaprine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Short-term Use of Cyclobenzaprine in Patients Undergoing Vaginal Surgery

Resource links provided by NLM:

Further study details as provided by NorthShore University HealthSystem Research Institute:

Primary Outcome Measures:
  • Faces Pain scale [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
  • Quantity of pain medications [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Constipation scale [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: April 2010
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Pill Drug: cyclobenzaprine
Cyclobenzaprine 5 mg TID for 7 days
Experimental: Flexeril Drug: cyclobenzaprine
Cyclobenzaprine 5 mg TID for 7 days


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ages 18-70 years old
  • Undergoing vaginal surgery with apical or posterior repair requiring hospitalization
  • Willingness to participate in the study
  • Normal neurological exam
  • English speaking

Exclusion Criteria:

  • Contraindication to NSAIDs
  • Allergy to hydrocodone, hydromorphone, or cyclobenzaprine
  • Renal disease
  • Use of any antidepressants including SSRI, SNRI, MAOI in the last 3 months
  • Glaucoma
  • Diabetes
  • Hyperthyroidism
  • Uncontrolled hypertension (>160/100 mm Hg)
  • History of chronic narcotic use in the last 3 months
  • History of pelvic pain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01081990

United States, Illinois
Evanston NorthShore University HealthSystem Recruiting
Evanston, Illinois, United States, 60201
Contact: Manhan K Vu, DO    847-570-2750      
Principal Investigator: Manhan K Vu, DO         
Sponsors and Collaborators
NorthShore University HealthSystem Research Institute
Principal Investigator: Kelly Jirschele, DO NorthShore University HealthSystem
  More Information

Responsible Party: Evanston Continence Center, Northshore Urogynecology, NorthShore University HealthSystem Research Institute Identifier: NCT01081990     History of Changes
Other Study ID Numbers: EH10-073 
Study First Received: March 4, 2010
Last Updated: July 23, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pain, Postoperative
Nervous System Diseases
Neurologic Manifestations
Pathologic Processes
Postoperative Complications
Signs and Symptoms
Adrenergic Agents
Adrenergic Uptake Inhibitors
Analgesics, Non-Narcotic
Antidepressive Agents
Antidepressive Agents, Tricyclic
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Muscle Relaxants, Central
Neuromuscular Agents
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Tranquilizing Agents processed this record on May 26, 2016